1,3-Diethoxy-2-(ethoxymethyl)-2-methylpropane | 253127-85-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1,3-Diethoxy-2-(ethoxymethyl)-2-methylpropane
• CAS: 253127-85-4
• 化学式: C₁₁H₂₄O₃
• 分子量: 204.31
• InChiKey: HKZWZPPFJCWXFC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Catalyst for trimerization of ethylene and process for trimerizing ethylene using the catalyst
  申请人：TOSOH CORPORATION

  公开号：US20020035029A1

  公开（公告）日：2002-03-21

  A catalyst used for trimerization of ethylene into 1-hexene is descrobed, which comprises (i) a specific organometallic complex having a neutral multidentate ligand having a tripod structure, (ii) an alkylaluminoxane, and an optional ingredient selected from: (iii) a halogenated inorganic compound, (iv) a specific alkyl group-containing compound, (v) a combination of a halogenated inorganic compound with a specific alkyl group-containing compound, (vi) an amine compound and/or an amide compound, and (vii) a combination of an amine compound and/or an amide compound with a specific alkyl group-containing compound.

  一种用于将乙烯三聚化为 1-己烯的催化剂已被脱色，它包括(i)一种特定的有机金属络合物，该络合物具有一个三脚架结构的中性多叉配体；(ii)一种烷基铝氧烷；以及一种选自下列物质的任选成分：(iii)卤代无机化合物；(iv)烷基铝氧烷： (iii) 卤化无机化合物、 (iv) 含特定烷基的化合物、 (v) 卤代无机化合物与特定含烷基化合物的组合、 (vi) 一种胺化合物和/或一种酰胺化合物，以及 (vii) 氨基化合物和/或酰胺化合物与特定含烷基化合物的组合。
• US20140343123A1
  申请人：——

  公开号：US20140343123A1

  公开（公告）日：2014-11-20
• COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
  申请人：ISIS PHARMACEUTICALS, INC.

  公开号：US20150126719A1

  公开（公告）日：2015-05-07

  Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein C-III (ApoCIII). In certain embodiments, the ApoCIII targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting ApoCIII for use in decreasing ApoCIII to treat, prevent, or ameliorate diseases, disorders or conditions related to ApoCIII. Certain diseases, disorders or conditions related to ApoCIII include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
• CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
  申请人：ISIS PHARMACEUTICALS, INC.

  公开号：US20150126718A1

  公开（公告）日：2015-05-07

  Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
• COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION
  申请人：ISIS PHARMACEUTICALS, INC.

  公开号：US20150126720A1

  公开（公告）日：2015-05-07

  Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.